ABSTRACT
Aim: Our aim was to determine the association between TGF-beta1 polymorphisms at position -509 C>T [rs1800469] and +915 G>C [rs1800471] and pancreatic cancer susceptibility in Iranian population
Background: Ninety percent of pancreatic cancer patients have less than 5-year overall survival and approximately 50% of cases were diagnosed with metastasis in the time of admission. Previous evidences have demonstrated the strong association between TGF-beta1 variations and cancer susceptibility so far
Methods: A total of 78 patients with pancreatic cancer and 94 healthy controls were enrolled in this case control study from 2007-2012. Genomic DNA was isolated from peripheral blood samples according to phenol chloroform extraction. The genotypes of TGF-beta1 rs rs1800469 and rs1800471 were determined using the polymerase chain reaction-restriction fragment length polymorphism method
Results: The mean age of cases and the control group were 64.50 +/- 13.718 and 40.12 +/- 16.001, respectively. For polymorphism-509 C>T, the frequency of TT genotype were 31 [33.0], CT, 47[50] and CC, 16 [17] in control and 19 [24.4], 45 [57.7] and 14 [17.9] in cases respectively. In position +915 G>C, the frequency of GG genotype was 84 [89.4] and GC, 10 [10.6] in control and 71 [91.0] and 7 [9] in cases, respectively. We did not observe any significant differences in the genotype and allele frequencies of the TGF-beta1-509 C>T [rs1800469] and codon +915 G>C [rs1800471] between the two study groups [P>0.05]
Conclusion: we found that TGF-beta1 gene polymorphisms rs1800469 and rs1800471 might not play a role in pancreatic cancer susceptibility in Iranian population
ABSTRACT
In this study, we determined the relationship between the serum level of IL-23 and the severity of ulcerative colitis [UC] among our population. A recent major breakthrough for describing the pathogenesis of intestinal tissue injury in inflammatory bowel disease [IBD] is the pathway related to interleukin-23 [IL-23]. We performed a prospective case-control study on a total of 85 new patients with ulcerative colitis, recruited from a general referral hospital. Forty ethnically matched healthy controls were also enrolled among hospital staffs and analyzed. Serum IL-23 level was quantified using an electrochemiluminescence immunoassay [ECLIA] method with an immunoassay analyzer. The mean serum IL-23 level in the group with ulcerative colitis was significantly higher than the healthy individuals [347.5 +/- 130.9 pg/ml versus 233.5 +/- 86.3 pg/ml; p<0.001]. There was a positive correlation between the serum level of IL-23 and disease duration [r = 0.27, p = 0.04]. Also, a direct relationship was found between the serum level of IL-23 and the severity of disease [mean IL-23 in mild UC = 296.2 +/- 51.2 pg/ml; in moderate UC = 356.1 +/- 142.9 pg/ml; and in severe UC=399.3 +/- 163.8 pg/ml, p=0.04]. Serum level of IL-23 is directly correlated with the duration and severity of ulcerative colitis